Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer

NCT06210971 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Rectal Cancer

Interventions

DRUG: liposomal irinotecan
DRUG: Capecitabine
RADIATION: Radiation threapy

Sponsor

Hebei Medical University Fourth Hospital